Docusign (NASDAQ: DOCU) CEO sells 26,250 shares in prearranged plan
by Danessa Lincoln · The Markets DailyWhat happened
Docusign, Inc. (NASDAQ: DOCU) President and CEO and director Allan C. Thygesen sold 26,250 shares on 2026-10-01. The Form 4 says the sale was made under a Rule 10b5-1 trading plan. It was split across three trades, with 7,475 shares sold at $68.53, 13,598 shares at $69.45 and 5,177 shares at $69.98. The shares changed hands for about $1.82 million total.
After the last transaction, Thygesen held 166,801 shares. The filing was signed on 2026-10-02. That leaves the CEO with a large remaining position, and the Form 4 gives investors a dated snapshot of management ownership rather than an operating update. Thygesen is still a large holder after the sale.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Shares sold | 26,250 shares | SEC Form 4 | |
| Sale value | about $1.82 million | SEC Form 4 | |
| Shares held after sale | 166,801 shares | SEC Form 4 | |
| Sale price range | from $68.53 to $69.98 per share | SEC Form 4 |
Read more: Docusign (DOCU) stock analysis and investment case
Why it matters
OptimistFi calculates the 26,250 shares were about 13.6% of Thygesen's pre-trade holding. That makes the move a meaningful trim, not a token trade. The comparison matters because the sale is large relative to the stake that remained. It also shows the sale was large relative to the stake that remained, which is why it is worth reading even as a planned trade.
OptimistFi's case is that Docusign works if its trusted e-signature position becomes the control point for broader digital agreement workflows, not if signing is absorbed as a cheap feature. This filing is mixed for that thesis because it shows the CEO reducing a personal stake, but the Rule 10b5-1 plan is the strongest caveat in the filing. A prearranged plan means the sale may not reflect a fresh negative view on the business.
Related: Docusign's AI Platform Takes a Bigger Share of Recurring Revenue
What's next
Docusign's next quarterly report is the next scheduled check on that case. A report that shows the company still anchors broader agreement workflows would strengthen the thesis, while a weaker report would make this planned sale easier to dismiss as routine. Until then, the Form 4 mainly shows that Thygesen sold shares at prices from $68.53 to $69.98 and still held 166,801 shares after the last trade. That keeps the filing focused on ownership, not operations.
More from OptimistFi
- DOCU stock: the Docusign thesis, its status and the next test to watch
- Century Therapeutics, Inc. (NASDAQ: IPSC) Adds Two CNTY-813 Batches
- Applied Digital Corporation (NASDAQ: APLD) Brings 250 MW Online
- ON Semiconductor Corporation (NASDAQ: ON) Cuts Its Deal Cost by 19%
- Stock research on every company OptimistFi covers
- Latest stock research and investment-case updates
- OptimistFi: evidence-first equity research
Sources
- SEC Form 4 — Allan C. Thygesen sale, post-sale holding, and Rule 10b5-1 plan
Read the full OptimistFi thesis on Docusign, Inc.: https://optimistfi.com/stocks/DOCU
See what would break the Docusign, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Docusign, Inc. investment case, its status and the next test to watch live on the Docusign, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.